CytomX Therapeutics, Inc.
CTMX · Pharmaceutical Preparations · 217.7M shares · +17%/yr ↑ shares · EDGAR filings ↗
Reference price $3.05 · est. market cap ~$664M — last insider sale, 2026-06-15 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D44Clinical/early-stage biotech — conditionally-activated-antibody clinical, funded.
Strengths
- Liquidity — current ratio 3.1 (42nd)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- Exec changeRecent 8-K item 5.02 8-K ↗
- Net lossNet loss (net margin -22.8%)
- Cash burnNegative free cash flow (-75.8M)
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Chronic dilutionShare count +17%/yr over 4y (dilution)
- Insider sellingInsider selling — 5 open-market sale(s) by 4 insider(s) (cluster of 4 insiders, ~$1M, last 6mo) Form 4 ↗
- Revenue declineRevenue -44.8% YoY
- Notable holderHeld by 4 notable fund(s): FMR LLC, CITADEL ADVISORS LLC, STATE STREET CORP +1 more (as of 2026-03-31)
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Operating margin
-29.3%
Net margin
-22.8%
Return on equity
-17.5%
Return on assets
-11.5%
Revenue growth (QoQ)
-44.8%
Net-income growth
-154.5%
Current ratio
3.1×
Free cash flow
-$76M
Tangible book value
$98M
Cash & investments
$137M
Cash runway
7q
Stock comp / revenue
8.3%
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-15 | Ogden Christopher | Sell | 1.6K | $3.05 |
| 2026-03-17 | McCarthy Sean A. | Sell | 119K | $6.42 |
| 2026-03-17 | BELVIN MARCIA | Sell | 31K | $6.42 |
| 2026-03-17 | Chu Yu-Waye | Sell | 21K | $6.42 |
| 2026-03-17 | Ogden Christopher | Sell | 19K | $6.42 |
| 2026-02-02 | BELVIN MARCIA | Grant | 60K | — |
| 2026-02-02 | Lester Rachael | Grant | 20K | — |
| 2026-02-02 | Chu Yu-Waye | Grant | 75K | — |
| 2026-02-02 | Ogden Christopher | Grant | 90K | — |
| 2026-02-02 | McCarthy Sean A. | Grant | 210K | — |
| 2025-11-06 | McCarthy Sean A. | Sell | 102K | $4.54 |
| 2025-06-16 | McCarthy Sean A. | Sell | 56K | $2.69 |
| 2025-06-16 | BELVIN MARCIA | Sell | 14K | $2.69 |
| 2025-06-16 | Ogden Christopher | Sell | 11K | $2.69 |
| 2025-06-13 | McCarthy Sean A. | Option exercise | 150K | — |
| 2025-06-13 | Ogden Christopher | Sell | 1.6K | $2.95 |
| 2025-06-13 | Ogden Christopher | Option exercise | 38K | — |
| 2025-06-13 | BELVIN MARCIA | Option exercise | 38K | — |
| 2025-03-18 | McCarthy Sean A. | Sell | 38K | $0.60 |
| 2025-03-18 | Ogden Christopher | Sell | 8.6K | $0.60 |
| 2025-03-18 | Chu Yu-Waye | Sell | 4.0K | $0.60 |
| 2025-03-18 | ROWLAND LLOYD A | Sell | 10K | $0.60 |
| 2025-03-18 | BELVIN MARCIA | Sell | 20K | $0.60 |
| 2025-02-04 | BELVIN MARCIA | Grant | 35K | — |
| 2025-02-04 | BELVIN MARCIA | Grant | 58K | — |
| 2025-02-04 | BELVIN MARCIA | Grant | 30K | — |
| 2025-02-04 | BELVIN MARCIA | Grant | 58K | — |
| 2025-02-04 | Chu Yu-Waye | Grant | 56K | — |
| 2025-02-04 | Chu Yu-Waye | Grant | 58K | — |
| 2025-02-04 | Ogden Christopher | Grant | 44K | — |
| 2025-02-04 | Ogden Christopher | Grant | 58K | — |
| 2025-02-04 | McCarthy Sean A. | Grant | 180K | — |
| 2025-02-04 | McCarthy Sean A. | Grant | 195K | — |
All non-derivative Form 4 activity (SEC), newest first.
Notable events (8-K)
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-22 | 2026-06-17 | 0001193125-26-277631 ↗ |
| 8-K | 2026-06-03 | 2026-05-29 | 0001193125-26-255467 ↗ |
| 8-K | 2026-05-07 | 2026-05-07 | 0001193125-26-211920 ↗ |
| 10-Q | 2026-05-07 | 2026-03-31 | 0001193125-26-211868 ↗ |
| 8-K | 2026-03-19 | 2026-03-17 | 0001193125-26-115958 ↗ |
| 8-K | 2026-03-16 | 2026-03-16 | 0001193125-26-107152 ↗ |
| 10-K | 2026-03-16 | 2025-12-31 | 0001193125-26-107146 ↗ |
| 8-K | 2025-11-06 | 2025-11-06 | 0001193125-25-269533 ↗ |
| 10-Q | 2025-11-06 | 2025-09-30 | 0001193125-25-269477 ↗ |
| 8-K | 2025-08-13 | 2025-08-13 | 0001193125-25-179463 ↗ |
| 8-K | 2025-08-07 | 2025-08-07 | 0000950170-25-105053 ↗ |
| 10-Q | 2025-08-07 | 2025-06-30 | 0000950170-25-104991 ↗ |